NCT04422366View on ClinicalTrials.gov

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

PHASE3RecruitingINTERVENTIONAL
Enrollment

8,000

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

September 15, 2027

Study Completion Date

September 15, 2029

Conditions
Cervical CancerVulvar CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AIS
Interventions
BIOLOGICAL

9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)

Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

BIOLOGICAL

GARDASIL®

Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule

Trial Locations (1)

Unknown

RECRUITING

Liuzhou center for disease control and prevention, Liuzhou

All Listed Sponsors
lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY

NCT04422366 - Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | Biotech Hunter | Biotech Hunter